X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2017 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Sun Pharma with Strides Arcolab - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

SUN PHARMA vs STRIDES SHASUN LTD - Comparison Results

SUN PHARMA    Change

Sun Pharma holds 3.7% share of the domestic pharma market (as per the latest ORG IMS MAT data) and has a strong presence in the lifestyle therapeutic segments. The company started focusing on the exports market in FY02, when it increased its stake to... More

STRIDES SHASUN LTD 
   Change

Strides Arcolab is an Indian pharmaceutical company headquartered at Bangalore. The company is primarily involved in two businesses notably the pharma business and the specialized sterile products business branded as Agila. This segment focuses large... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    SUN PHARMA STRIDES SHASUN LTD SUN PHARMA/
STRIDES SHASUN LTD
 
P/E (TTM) x 15.0 13.9 108.3% View Chart
P/BV x 3.5 1.9 188.2% View Chart
Dividend Yield % 0.2 0.6 39.1%  

Financials

 SUN PHARMA   STRIDES SHASUN LTD
EQUITY SHARE DATA
    SUN PHARMA
Mar-16
STRIDES SHASUN LTD
Mar-16
SUN PHARMA/
STRIDES SHASUN LTD
5-Yr Chart
Click to enlarge
High Rs1,2011,413 85.0%   
Low Rs706848 83.3%   
Sales per share (Unadj.) Rs117.5353.3 33.3%  
Earnings per share (Unadj.) Rs19.623.4 83.8%  
Cash flow per share (Unadj.) Rs23.841.0 58.1%  
Dividends per share (Unadj.) Rs1.005.00 20.0%  
Dividend yield (eoy) %0.10.4 23.7%  
Book value per share (Unadj.) Rs130.5320.4 40.7%  
Shares outstanding (eoy) m2,406.6089.35 2,693.5%   
Bonus/Rights/Conversions -ESOP-  
Price / Sales ratio x8.13.2 253.7%   
Avg P/E ratio x48.748.3 100.7%  
P/CF ratio (eoy) x40.127.6 145.2%  
Price / Book Value ratio x7.33.5 207.2%  
Dividend payout %5.121.4 23.9%   
Avg Mkt Cap Rs m2,294,813100,988 2,272.4%   
No. of employees `00014.74.7 314.4%   
Total wages/salary Rs m47,9714,988 961.7%   
Avg. sales/employee Rs Th19,169.86,730.0 284.8%   
Avg. wages/employee Rs Th3,253.01,063.6 305.8%   
Avg. net profit/employee Rs Th3,197.9445.5 717.8%   
INCOME DATA
Net Sales Rs m282,69731,564 895.6%  
Other income Rs m6,1701,212 509.0%   
Total revenues Rs m288,86732,776 881.3%   
Gross profit Rs m83,2395,213 1,596.8%  
Depreciation Rs m10,1351,573 644.4%   
Interest Rs m4,7691,803 264.5%   
Profit before tax Rs m74,5053,049 2,443.4%   
Minority Interest Rs m-11,126127 -8,788.3%   
Prior Period Items Rs m-19-27 69.5%   
Extraordinary Inc (Exp) Rs m-6,852-371 1,847.2%   
Tax Rs m9,349689 1,357.8%   
Profit after tax Rs m47,1592,089 2,257.0%  
Gross profit margin %29.416.5 178.3%  
Effective tax rate %12.522.6 55.6%   
Net profit margin %16.76.6 252.0%  
BALANCE SHEET DATA
Current assets Rs m308,64635,949 858.6%   
Current liabilities Rs m132,47719,402 682.8%   
Net working cap to sales %62.352.4 118.9%  
Current ratio x2.31.9 125.7%  
Inventory Days Days8371 117.0%  
Debtors Days Days88127 69.2%  
Net fixed assets Rs m133,60634,478 387.5%   
Share capital Rs m2,407894 269.3%   
"Free" reserves Rs m266,90922,601 1,181.0%   
Net worth Rs m314,04228,632 1,096.8%   
Long term debt Rs m31,16727,455 113.5%   
Total assets Rs m542,19676,591 707.9%  
Interest coverage x16.62.7 617.7%   
Debt to equity ratio x0.11.0 10.4%  
Sales to assets ratio x0.50.4 126.5%   
Return on assets %9.65.1 188.4%  
Return on equity %15.07.3 205.8%  
Return on capital %17.88.2 217.3%  
Exports to sales %14.048.1 29.1%   
Imports to sales %3.114.5 21.7%   
Exports (fob) Rs m39,57215,192 260.5%   
Imports (cif) Rs m8,8824,565 194.6%   
Fx inflow Rs m42,17116,612 253.9%   
Fx outflow Rs m21,5835,292 407.8%   
Net fx Rs m20,58811,320 181.9%   
CASH FLOW
From Operations Rs m67,694717 9,446.5%  
From Investments Rs m-44,549-22,284 199.9%  
From Financial Activity Rs m-19,24329,488 -65.3%  
Net Cashflow Rs m3,9028,073 48.3%  

Share Holding

Indian Promoters % 63.7 27.7 230.0%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 5.1 37.8 13.6%  
FIIs % 23.0 8.6 267.4%  
ADR/GDR % 0.0 0.0 -  
Free float % 8.3 25.9 32.0%  
Shareholders   133,026 56,241 236.5%  
Pledged promoter(s) holding % 0.5 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare SUN PHARMA With:   ABBOTT INDIA  JUBILANT LIFE SCIENCES  DIVIS LABORATORIES  PIRAMAL ENTERPRISES  NATCO PHARMA  

Compare SUN PHARMA With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Infosys Woes, Insurance IPOs and Top Stocks in Action(Pre-Open)

On Monday, the share markets in India slumped in the final hours of trade and finished the day in red.The BSE Sensex closed lower by 266 points to end at 31,259.

Related Views on News

Sun Pharma: Bottomline Slips into the Red Amidst Challenging Environment (Quarterly Results Update - Detailed)

Aug 14, 2017

A challenging environment and one-time expense pushes Sun Pharma into a loss in the first quarter.

Sun Pharma: Price Erosion in US Impacts Growth (Quarterly Results Update - Detailed)

May 30, 2017

US markets decline while other geographies grow in the quarter.

Lupin: Bigger Challenges or Bigger Margin of Safety? (Quarterly Results Update - Detailed)

Aug 14, 2017

GST impact coupled with price erosion in US leads to lower profits for the quarter.

Dr Reddy's: US Pressure Continues to Haunt (Quarterly Results Update - Detailed)

Aug 8, 2017

Profits plunge due to higher raw material costs.

Biocon: Lower Licensing Income Leads to Muted Growth for the Quarter (Quarterly Results Update - Detailed)

Jun 23, 2017

Net Profit lower due to exceptional items in the previous year.

More Views on News

Most Popular

A 'Backdoor' to Multibaggers: It's Like Investing in Asian Paints Ten Years Ago(The 5 Minute Wrapup)

Aug 10, 2017

Don't miss these proxy bets on growing companies or in a few years you will be looking back with regret.

The Most Important Innovation in Finance Since Gold Coins(Vivek Kaul's Diary)

Aug 10, 2017

Bill connects the dots...between money and growth, real money and real resources, gold and cryptocurrencies...and between gold, cryptocurrencies, and time.

Signs of Life in the India VIX(Daily Profit Hunter)

Aug 12, 2017

The India VIX is up 36% in the last week. Fear has gone up but is still low by historical standards.

Bitcoin Continues Stellar Rise(Chart Of The Day)

Aug 10, 2017

Bitcoin hits an all-time high, is there more upside left?

5 Steps To Become Financially Independent(Outside View)

Aug 16, 2017

Ensure your financial Independence, and pledge to start the journey towards financial freedom today!

More

Become A Smarter Investor In
Just 5 Minutes

Multibagger Stocks Guide 2017
Get our special report, Multibagger Stocks Guide (2017 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

SUN PHARMA SHARE PRICE


Aug 21, 2017 (Close)

TRACK SUN PHARMA

  • Track your investment in SUN PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

SUN PHARMA - ASTRAZENECA PHARMA COMPARISON

COMPARE SUN PHARMA WITH

MARKET STATS